Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLUTION: disitamab vedotin + tislelizumab + bevacizumab in HER2-altered advanced NSCLC
ChiCTR2300077938Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin, tislelizumab and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: confirmed objective response rate. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
disitamab vedotintislelizumabbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300077938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077938.